orforglipron vs semaglutide Orforglipron: The Oral Non-Peptide GLP-1 Agonist ACHIEVE-3 results: Lilly's Orfoglipron performance

They are fermenting

Enrollees with obesity and overweight diagnoses have higher health spending than those without such diagnoses In 2021, people with large employer private insurance coverage who had an obesity or overweight diagnosis had an average of $12,588 in total annual health costs, which is more than double the $4,699 in health spending for those with no obesity or overweight diagnosis on their health insurance claims for that year

Semaglutide has shown to be most effective in patients who also followed healthy lifestyle changes in nutrition and movement, so you still need to implement those lifestyle changes, which may prove difficult to do alone

Study of the Potential Association of Adipose Tissue GLP-1 Receptor with Obesity and Insulin Resistance

The difference is the delivery method (vial and syringe versus pre-filled pen) and the absence of brand-name marketing and patent premiums